[ad_1]
ImmuCell (NASDAQ:ICCC) stated its complete gross sales for the yr ended Dec. 31 fell 6% Y/Y, as the corporate was damage by decrease manufacturing output throughout the first 10 months of the yr.
The corporate reported $17.5 million in its complete gross sales for the yr ended Dec. 31, as in comparison with $18.6 million in 2022.
ICCC stated for its three months ended Dec. 31, the gross sales had been up 30% Y/Y.
The corporate reported $17.5 million in its complete gross sales for the yr ended Dec. 31, as in comparison with $18.6 million in 2022.
ICCC stated for its three months ended Dec. 31, the gross sales had been up 30% Y/Y.
[ad_2]
Source link
